Comparative Pharmacology
Head-to-head clinical analysis: DECABID versus LORATADINE REDIDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECABID versus LORATADINE REDIDOSE.
DECABID vs LORATADINE REDIDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Decabid is a combination of chlorpheniramine (antihistamine) and pseudoephedrine (decongestant). Chlorpheniramine competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine acts as a sympathomimetic agent, stimulating alpha-adrenergic receptors to cause vasoconstriction, reducing nasal congestion.
Selective peripheral H1 receptor antagonist; inhibits histamine release from mast cells.
1 capsule orally every 12 hours; each capsule contains 10 mg phenylephrine hydrochloride and 75 mg carbinoxamine maleate.
10 mg orally once daily
None Documented
None Documented
12 hours (terminal); prolonged to 24 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is 8–14 hours (mean ~12 hours) for desloratadine (active metabolite); parent loratadine half-life ~3–20 hours (mean ~8 hours). Clinically, once-daily dosing maintains steady state in 5–7 days.
Renal (50% as unchanged drug), fecal (40% as metabolites), biliary (10% as glucuronide conjugates)
Renal (approximately 40% as metabolites), biliary/fecal (approximately 60% as metabolites). Less than 1% excreted unchanged in urine.
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine